Table 1.
Baseline characteristics of men with PD
| Characteristic | Volume-loss deformity (n = 83, 65%) | Non–volume-loss deformity (n = 45, 35%) | P value∗ |
|---|---|---|---|
| Age, median (IQR) | 55 (45–61) | 54 (45–63) | .82 |
| Race, frequency (%) | .28 | ||
| White | 39 (47) | 15 (33) | |
| Black | 4 (5) | 4 (9) | |
| Unknown/Other | 40 (48) | 26 (58) | |
| Ethnicity, frequency (%) | .05 | ||
| Hispanic | 4 (5) | 6 (13) | |
| Not Hispanic | 50 (60) | 18 (40) | |
| Unknown | 29 (35) | 21 (47) | |
| BMI, median (IQR) | 26 (24–29) | 27 (25–28) | .61 |
| Smoking history, frequency (%) | 26 (31) | 13 (29) | .78 |
| Penile trauma, frequency (%) | 16 (19) | 12 (27) | .33 |
| PD duration, months, median (IQR) | 14 (5–36) | 12 (6–36) | .91 |
| HTN, frequency (%) | 19 (23) | 14 (31) | .31 |
| DM, frequency (%) | 10 (12) | 5 (11) | .88 |
| Hypercholesterolemia, frequency (%) | 20 (24) | 8 (18) | .41 |
| BPH, frequency (%) | 8 (10) | 5 (11) | .79 |
| Prostate cancer, frequency (%) | 5 (6) | 3 (7) | .89 |
| Phosphodiesterase-5 inhibitors, frequency (%) | 34 (41) | 21 (47) | .53 |
| Prior non-surgical PD therapy, frequency (%) | 36 (43) | 18 (40) | .71 |
BMI = body mass index; BPH = benign prostatic hyperplasia; HTN = hypertension; IQR = interquartile range; PD = Peyronie’s disease.
∗
P values were calculated using the chi-square test or Mann-Whitney U test.